| Literature DB >> 27706020 |
Stefano Vendrame1, Cristian Del Bo'2, Salvatore Ciappellano3, Patrizia Riso4, Dorothy Klimis-Zacas5.
Abstract
Metabolic Syndrome is a cluster of risk factors which often includes central obesity, dyslipidemia, insulin resistance, glucose intolerance, hypertension, endothelial dysfunction, as well as a pro-inflammatory, pro-oxidant, and pro-thrombotic environment. This leads to a dramatically increased risk of developing type II diabetes mellitus and cardiovascular disease, which is the leading cause of death both in the United States and worldwide. Increasing evidence suggests that berry fruit consumption has a significant potential in the prevention and treatment of most risk factors associated with Metabolic Syndrome and its cardiovascular complications in the human population. This is likely due to the presence of polyphenols with known antioxidant and anti-inflammatory effects, such as anthocyanins and/or phenolic acids. The present review summarizes the findings of recent dietary interventions with berry fruits on human subjects with or at risk of Metabolic Syndrome. It also discusses the potential role of berries as part of a dietary strategy which could greatly reduce the need for pharmacotherapy, associated with potentially deleterious side effects and constituting a considerable financial burden.Entities:
Keywords: Metabolic Syndrome; berries; dietary intervention studies; humans
Year: 2016 PMID: 27706020 PMCID: PMC5187532 DOI: 10.3390/antiox5040034
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1A flow chart highlighting study selection. * Studies were identified according to the following keywords: “berry”, “Metabolic Syndrome”, “overweight”, “obesity”, “hypertension”, “hypercholesterolemia”, “hyperlipemia”, “Type II diabetes”, and “humans”. ** Studies were excluded because they used a mix of fruit and vegetables and other foods in which berries were not the main food.
Effect of berry consumption on Metabolic Syndrome and associated risk factors.
| Berry | Intervention | Participants | Dose | Main findings | References |
|---|---|---|---|---|---|
| Blueberry | 8-week, randomized, double-blind, placebo-controlled, parallel intervention | Forty-eight postmenopausal women (Blueberry group: BMI 30.1 ± 5.94 kg/m2; age 59.7 ± 4.58 year; Control group: BMI 32.7 ± 6.79 kg/m2; age 57.3 ± 4.76 year) with pre- and stage 1-hypertension | ↓systolic, diastolic blood pressure and brachial-ankle pulse wave velocity | Johnson et al. [ | |
| 6-week randomized, double-blind, placebo-controlled, parallel intervention | Forty-four subjects with metabolic syndrome (Blueberry group: BMI 35.2 ± 0.8 kg/m2; age 55 ± 2 year; Control group: BMI 36.0 ± 1.1 kg/m2; age 59 ± 2 year) | ↑endothelial function | Stull et al. [ | ||
| 6-week, randomized, placebo-controlled, crossover intervention | Eighteen male (BMI 24.8 ± 2.6 kg/m2; age 47.8 ± 9.7 year) with CVD risk factors | ↓Endogenous and oxidatively-induced DNA damage in PBMCs | Riso et al. [ | ||
| 6-week, randomized, double-blinded, placebo-controlled, parallel intervention | Twenty-seven (BMI between 32 and 45 kg/m2; age > 20 year) obese, insulin-resistant subjects | ↑insulin sensitivity | Stull et al. [ | ||
| 8-week, randomized, single-blinded, controlled parallel intervention | Forty-eight subjects with metabolic syndrome (4 males and 44 females; BMI 37.8 ± 2.3 kg/m2; age 50.0 ± 3.0 year) | ↓systolic and diastolic blood pressure | Basu et al. [ | ||
| Bilberry | 8-week, randomized, controlled, parallel intervention | Twenty-seven subjects (Bilberry group: BMI 31.4 ± 4.7 kg/m2; age 53 ± 6 year; Control group: 32.9 ± 3.4 year; age 50 ± 7 year) with metabolic syndrome | ↓serum levels of hs-CRP, IL-6, IL-12 and inflammation score. | Kolehmainen et al. [ | |
| 5-week, randomized, cross-over intervention | Eighty overweight and obese women (BMI 29.6 ± 2.1 kg/m2; age 44.2 ± 6.2 year; 21 subjects meeting metabolic syndrome criteria) | ↓body weight, waist circumference, VCAM-1, TNF-α, adiponectin | Lehtonen et al. [ | ||
| 4-week, randomized, controlled, parallel intervention | Sixty-two subjects (Bilberry group: BMI range 19.9–31.7 kg/m2; age range 34–68 year; Control group: BMI range 17.8–31.5 kg/m2; age range 30–68 year) with CVD risk factors | ↓serum levels of CRP, IL-6, IL-15, TNF-α, MIG | Karlsen et al. [ | ||
| Cranberry | 4-week, placebo-controlled double-blind, crossover intervention | Thirty-five abdominally obese men (age 45 ± 10 year, BMI 28.3 ± 2.4 kg/m2 and a waist circumference ≥90 cm) with metabolic ( | ↓arterial stiffness and global endothelial function | Ruel et al. [ | |
| 60 days, parallel intervention | Fifty-six subjects (cranberry group: BMI 30.9 kg/m2 median, age 51.0 year median; control group: BMI 34.0 kg/m2 median, age 48.5 year median) with metabolic syndrome | ↓serum homocysteine levels, lipoperoxidation, protein oxidation | Simão et al. [ | ||
| 12-week, randomized, double-blind, parallel intervention | Fifty-eight (BMI 28.8 ± 3.6 kg/m2, age 54.8 ± 9.1 year) Type II diabetic subjects | ↓glucose, ApoB | Shidfar et al. [ | ||
| Post-prandial 4-week, randomized, placebo-controlled, cross-over intervention | Fifteen (BMI not reported, age 62 ± 8 year, 13% female) subjects with coronary artery diseases | ↑flow mediated dilation and lnPAT score as markers of endothelial function | Dohadwala et al. [ | ||
| 8-week, randomized double-blind, placebo-controlled, parallel intervention | Thirty-one (BMI 40.0 ± 7.7 kg/m2, age 52.0 ± 8.0 year) female with metabolic syndrome | ↓ox-LDL, MDA & HNE plasma/serum levels | Basu et al. [ | ||
| Post-prandial cross-over intervention | Thirteen (6 female and 7 male) noninsulin-dependent subjects (age 61.6 ± 2.3 year, BMI 33.25 ± 1.22 kg/m2) | ↓glycemic and insulinemic response following SDC-LS | Wilson et al. [ | ||
| 12-week intervention (three 4-week intervention with 125, 250 and 500 mL/day cranberry juice) | Thirty (BMI 27.8 ± 3.2 kg/m2, age 51 ± 10 year; 9 subjects with metabolic syndrome and 21 without metabolic syndrome) abdominally obese men | ↓ox-LDL following 250 and 500 mL cranberry juice | Ruel et al. [ | ||
| 12-week, randomized, placebo-controlled, double-blind, parallel intervention | Thirty (16 males and 14 females) Type II diabetic subjects (Cranberry group: 9/6 male/female, BMI 26.2 ± 0.7 kg/m2, age 65 ± 2 year; Control group: 7/8 male/female, BMI 25.9 ± 1.0 kg/m2, age 66 ± 2 year) | ↓Total cholesterol, Total: HDL cholesterol ratio, LDL cholesterol | Lee et al. [ | ||
| Post-prandial intervention | Twelve (6 male and 6 female) type II diabetic subjects (age 65.3 ± 2.3 year, BMI 34.7 ± 1.6 kg/m2 | ↓plasma insulin and glycemic response following LCCBJ | Wilson et al. [ | ||
| 12-week intervention (three 4-week intervention with 125, 250, and 500 mL/day cranberry juice) | Thirty (BMI 27.8 ± 3.3 kg/m2, age 51 ± 10 year) abdominally obese men | ↓body weight, BMI, waist circumference, waist-to-hip ratio, total:HDL cholesterol apo B, after intervention with 250 and 500 mL cranberry juice | Ruel et al. [ | ||
| 2-week intervention | Twenty-one (BMI 26.9 ± 3.8 kg/m2, age 38 ± 8 year) abdominally obese-dyslipidemic men | ↓BMI, plasma ox-LDL levels | Ruel et al. [ | ||
| 12-week randomized, controlled, parallel intervention | Twenty-seven Type II diabetic subjects (cranberry group: 14 subjects, 6 women and 8 men, BMI not reported, age 57.9 ± 10.6 year; placebo group: 13 subjects 6 women and 7 men, BMI not reported, age 52.6 ± 13.7 year) | ↑insulin levels after placebo treatment | Chambers & Camire [ | ||
| Raspberry | 14-day (4-day black-raspberry intake, post-prandial, randomized, cross-over intervention, wash-out and 4-day black-raspberry intake) | Ten older overweight and obese (BMI, 31.4 ± 2.7 kg/m2, age 64.7 ± 6.9 year) males | ↓serum IL-6 levels | Sardo et al. [ | |
| 12-week, randomized, controlled, parallel intervention | Seventy-seven subjects (berry group: BMI, 26.3 ± 4.3 kg/m2, age 58.0 ± 9.2 year; control group: BMI, 25.1 ± 4.0 kg/m2, age 60.1 ± 9.5 year) with metabolic syndrome | ↓total cholesterol level total cholesterol/HDL ratio IL-6, TNF-α | Jeong et al. [ | ||
| Chokeberry | 4-week intervention | Twenty-three subjects (BMI, not reported, age 47.5 ± 10.4 year) with hypertension | ↓systolic and diastolic blood pressure, heart rate high-frequency power, heart rate very low frequency, standard deviation of normal RR intervals Holter ECG | Kardum et al. [ | |
| 4-week intervention | Twenty women (BMI, 36.1 ± 4.4 kg/m2; age 53.0 ± 5.4 year) with abdominal obesity | ↓BMI, waist circumference, systolic blood pressure, serum HDL cholesterol, erythrocytes monounsaturated fatty acids, n6/n3 ratio | Kardum et al. [ | ||
| 8-week intervention | Fifty-two subjects (42–65 years old; berry group: 38 subjects, BMI 31.1 ± 3.3 kg/m2; control group: 14 healthy subjects; BMI 24.4 ± 1.5 kg/m2) with metabolic syndrome | ↓serum total and LDL cholesterol, triglycerides, coagulation and platelet aggregation parameters | Sikora et al. [ | ||
| 18-week (6-week intervention + 6-week wash-out + 6 week intervention) intervention | Fifty-eight men (BMI 27.7 ± 2.9 kg/m2; age 54.1 ± 5.6 year) with mild hypercholesterolemia | ↓serum total and LDL cholesterol, triglycerides, glucose, homocysteine and fibrinogen, blood pressure | Skoczyñska et al. [ | ||
| Strawberry | Post-prandial, randomized, controlled, 4-arm, crossover intervention | Twenty-one (BMI 40.2 ± 7.2 kg/m2; age 39.8 ± 13.8 year) subjects with abdominal obesity and insulin-resistance | ↓plasma insulin, insulin: incremental increase, glucose: incremental increase, insulin: glucose ratio after 40 g FDS consumption | Park et al. [ | |
| 12-week, randomized, controlled, parallel intervention | Sixty volunteers with CVD risk factors | ↓serum total and LDL-cholesterol, derived small LDL particles, MDA and HNE levels following HD-FDS intervention. | Basu et al. [ | ||
| 6-week, randomized, double-blind, controlled, parallel intervention | Thirty-six diabetic subjects (berry group: | ↓diastolic blood pressure | Amani et al. [ | ||
| 6-week, randomized double-blind controlled intervention | Thirty-six subjects (23 females/13 males) with type 2 diabetes (berry group: 19 diabetic subjects; BMI, 27.32 ± 3.26 kg/m2; age, 51.88 ± 8.26 year; control group: 17 diabetic subjects; BMI, 28.70 ± 4.24 kg/m2, age, 51.17 ± 13.88 year) | ↓MDA, HbA1c and hs-CRP serum levels | Moazen et al. [ | ||
| 7-week double-blind, randomized, cross-over intervention | Twenty obese subjects (BMI between 30 and 40 kg/m2, age between 20 and 50 year) | ↓Serum total cholesterol, small HDL particles, LDL size, fibrinogen | Zunino et al. [ | ||
| Post-prandial, randomized, single-blind, placebo-controlled, cross-over intervention | Twenty-six overweight subjects (BMI, 29.2 ± 2.3 kg/m2; age, 50.9 ± 15.0 year) | ↓serum hs-CRP, IL-6 and insulin levels | Ederisinghe et al. [ | ||
| 6-week, randomized, single-blind, placebo-controlled, parallel intervention + post-prandial high carbohydrates fat meal | Twenty-four overweight and obese subjects (BMI, 29.2 ± 2.3 kg/m2; age, 50.9 ± 15.0 year) | =serum levels of glucose, insulin, hs-CRP, IL-6, PAI-1, IL-1β, TNF-α after 6-week intervention | Ellis et al. [ | ||
| 6-week, randomized, single-blind, placebo-controlled, crossover intervention After 6 weeks subjects consumed a high fat meal (post-prandial) | Twenty-four hyperlipidemic subjects (14 female, 10 male; BMI, 29.2 ± 2.3 kg/m2, age 50.9 ± 15 year) | ↓serum total, LDL and HDL cholesterol, TG after 6 weeks | Burton-Freeman et al. [ | ||
| 8-week intervention | Twenty-seven subjects (BMI: 37.5 ± 2.15 kg/m2; age: 47.0 ± 3.0 year) with metabolic syndrome | ↓total and LDL-cholesterol, small LDL particles, VCAM-1 | Basu et al. [ | ||
| 4-week intervention | Sixteen female (mean BMI, 38.6 ± 2.3 kg/m2; range age, 39–71 year) with metabolic syndrome | ↓serum total and LDL-cholesterol, MDA and HNE levels | Basu et al. [ | ||
| 4-week, randomized, controlled, cross-over intervention | Twenty-eight hyperlipidemic subjects (range BMI, 19.8–32.3 kg/m2; range age, 38–75 years) | ↓MDA plasma absolute concentration and molar ration of LDL-cholesterol at 4 weeks compared to placebo | Jenkins et al. [ | ||
| Whortleberry | 4-week, randomized, double-blind, placebo-controlled, parallel intervention | Fifty hyperlipidemic subjects (berry group: twenty-five, 15 females/10 males; BMI, 25.40 ± 1.75 kg/m2; age, 48.08 ± 16.39 year; control group: twenty-five hyperlipidemic subjects, 15 females/10 males; BMI, 25.21 ± 2.01 kg/m2; age, 46.36 ± 16.59 year) | ↓serum total, LDL-cholesterol, TG and plasma MDA levels | Soltani et al. [ | |
| Berry mix | 12-week, randomized, double-blinded, placebo-controlled intervention | One hundred and thirty-three hypertensive subjects (BMI, 26 ± 3 kg/m2, age 62 ± 6 year) | ↓blood pressure | Tjelle et al. [ | |
| 12-week, randomized, controlled, parallel intervention | Twenty subjects (berry group: BMI, 31.8 ± 4.4 kg/m2, age 53.0 ± 6.5 year; control group: BMI, 32.9 ± 3.4 kg/m2, age 49.8 ± 7.1 year) with symptoms of metabolic syndrome | ↓serum leptin levels | Puupponen-Pimiä et al. [ | ||
| 20-week, randomized, controlled, parallel intervention | Sixty-one female subjects 35–52 years (berry group: BMI 29.3 ± 2.2 kg/m2, control group: BMI 29.5 ± 1.8 kg/m2) with metabolic syndrome | ↓plasma ALT levels | Lehtonen et al. [ |
Legend: BMI: body mass index; NO: nitric oxide; hs-CRP: high sensitive C-reactive protein; ICAM: Intercellular Adhesion Molecule 1; VCAM: Vascular cell adhesion molecule 1; ALT/ALAT: alanine aminotransferase; TRAP: total radical trapping antioxidant parameter; TG: triglycerides; LDL: low density lipoprotein; ox-LDL: oxidized low density lipoprotein; HDL: high density lipoprotein; MDA: malondialdehyde; PBMC: peripheral blood mononuclear cell; HNE: 4-hydroxynonenal; IL-1β: interleukin-1β; IL-6: interleukin-6; TNF-α:tumor necrosis factor-alpha; PAI-1: plasminogen activator inhibitor-1; HOMA-IR: Insulin resistance index; GST: glutathione S-transferase; SOD: superoxide dismutase; GPx: glutathione peroxidase; GHbAC: Glycated hemoglobin A1C; PAT: peripheral arterial function; PON1: paraxonase1; MIG: monokine induced by interferon; MMD: monocyte to macrophage differentiation associated; CCR2: chemokine (C-C motif) receptor 2.